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ARTICLE
Genome-wide association study of 23,500
individuals identifies 7 loci associated with brain
ventricular volume
Dina Vojinovic et al.#
The volume of the lateral ventricles (LV) increases with age and their abnormal enlargement
is a key feature of several neurological and psychiatric diseases. Although lateral ventricular
volume is heritable, a comprehensive investigation of its genetic determinants is lacking. In
this meta-analysis of genome-wide association studies of 23,533 healthy middle-aged to
elderly individuals from 26 population-based cohorts, we identify 7 genetic loci associated
with LV volume. These loci map to chromosomes 3q28, 7p22.3, 10p12.31, 11q23.1, 12q23.3,
16q24.2, and 22q13.1 and implicate pathways related to tau pathology, S1P signaling, and
cytoskeleton organization. We also report a significant genetic overlap between the thalamus
and LV volumes (ρgenetic=−0.59, p-value= 3.14 × 10−6), suggesting that these brain
structures may share a common biology. These genetic associations of LV volume provide
insights into brain morphology.
DOI: 10.1038/s41467-018-06234-w OPEN
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The volume of lateral ventricles increases in normalaging1–4. The enlargement of lateral ventricles has alsobeen suggested in various complex neurological disorders
such as Alzheimer’s disease, vascular dementia, and Parkinson’s
disease5–8 as well as psychiatric disorders such as schizophrenia
and bipolar disorder9–11. Furthermore, ventricular enlargement
has been associated with poor cognitive functioning and cerebral
small vessel disease pathology12–14. Even though it might be
intuitive to interpret ventricular expansion primarily as an indi-
cator of brain shrinkage after the onset of the disorder, recent
studies have provided evidence against this notion15,16. The size
of lateral ventricles is influenced by genetic factors with herit-
ability estimated to be 54%, on average16, but changing with age,
from 32–35% in childhood to about 75% in late middle and older
age16. Even though the size of surrounding gray matter structures
is also heritable17–19, ventricular volume is reported to be
genetically independent of other brain regions surrounding the
ventricles20. Similarly, ventricular enlargement in schizophrenia
does not appear to be linked to volume reduction in the sur-
rounding structures15.
Elucidating the genetic contribution to inter-individual varia-
tion in lateral ventricular volume can thus provide important
insights and better understanding of the complex genetic archi-
tecture of brain structures and related neurological and psychia-
tric disorders. Candidate gene studies have identified single-
nucleotide polymorphisms (SNPs) mapping to Catechol-O-
Methyltransferase (COMT) and Neuregulin 1 (NRG1) genes as
associated with larger lateral ventricular volume in patients with
the first episode of non-affective psychosis21,22. However, a
comprehensive investigation of the genetic determinants of lateral
ventricular volume is lacking.
Here, we perform a genome-wide association (GWA) meta-
analysis of 23,533 middle-aged to elderly individuals from
population-based cohorts participating in the Cohorts for Heart
and Aging Research in Genomic Epidemiology (CHARGE)
consortium in order to identify common genetic variants that
influence lateral ventricle volume. We apply a commonly used
two-stage GWA design followed by a joint analysis approach that
combines information across the stages and provides greater
power23. We identify 7 genetic loci associated with lateral ven-
tricular volume and report genome-wide overlap with thalamus
volume.
Results
Genome-wide association results. The overview of study design
is illustrated in Supplementary Fig. 1. The GWA results from
12 studies were combined in stage 1 and subsequently evaluated
in an independent sample from 14 studies in stage 2. Finally, the
results of stage 1 and stage 2 analyses were combined in stage 3.
Detailed information on study participants, image acquisition and
genotyping is provided in Supplementary Note 1 and Supple-
mentary Data 1–3.
The results of the stage 1 meta-analysis (N= 11,396) are
illustrated in Supplementary Fig. 2. The quantile-quantile plot
suggests that potential population stratification and/or cryptic
relatedness are well controlled after genomic correction (λ= 1.04)
(Supplementary Fig. 2, Supplementary Table 1). The stage 1 meta-
analysis identified 146 significant variant associations, mapping to
three chromosomal regions at 3q28, 7p22.3, and 16q24.2 (Table 1).
All 146 stage 1 significant associations replicated in the stage 2
meta-analysis (N= 12,137) with the same direction of effect at
Bonferroni adjusted significance (p-value= 5 × 10−3, Supplemen-
tary Data 4), except one SNP (p-value= 7.6 × 10−3). Subsequently,
the results from all individual studies were combined in the stage 3
GWA meta-analysis (N= 23,533). The quantile–quantile plot
showed again adequate control of population stratification or
relatedness (Supplementary Fig. 3). The combined stage 3 GWA
meta-analysis identified 314 additional significant associations
mapping to four additional chromosomal regions at 10p12.31,
11q23.1, 12q23.3, and 22q13.1 (Figs. 1, 2, Table 1). The effect size
for the lead variant mapped to 10p12.31 locus was correlated with
mean age of the cohort (r= 0.50, p-value= 0.03) (Supplementary
Fig. 4). No correlation was found for the other lead variants
(Supplementary Fig. 5–10).
Even though cohorts of European (EA) and African-American
(AA) ancestry were included, all significant associations were
mainly driven by EA samples (Supplementary Fig. 11–12). The
direction of effect size across the EA cohorts for the seven lead
variants was generally concordant and showed no evidence of any
single cohort driving the associations (Supplementary Fig. 11).
Despite the different methods of phenotyping across the cohorts,
the cohorts with different phenotyping methods showed evidence
of effect suggesting that there is limited heterogeneity in effects
(Supplementary Fig. 12).
To investigate whether seven lead variants have an effect in
early life, childhood, the analyses were carried out in a children’s
cohort of 1141 participants from Generation R study. The
percentage of lead variants showing consistent direction of effect
with stage 3 was 85.7% (6 out of 7, binomial p-value= 0.05)
(Supplementary Data 4), and a variant mapped to the 12q23.3
region showed nominal association with lateral ventricular
volume in the children’s cohort (Zscore = −2.56, p-value=
0.01). Additionally, three out of seven lead variants (or their
proxies; r2 > 0.7) showed pleiotropic association (p-value < 5 ×
10−8) with other traits according to the PhenoScanner database
(Supplementary Data 5)24.
To capture gender-based differences, sex-stratified GWA
analysis was performed (Nmen= 10,358; Nwomen= 12,872).
None of the 15,660,719 variants that were tested for heterogeneity
between men and women reached genome-wide significance
threshold (Supplementary Fig. 13). However, an indel located at
4q35.2 showed suggestive evidence of association in men
(4:187559262:C_CAA, p-value= 5.43 × 10−8) but not in women
(p-value= 0.88).
Independent signals within loci. The conditional and joint
(COJO) analysis using the Genome-wide Complex Trait Analysis
(GCTA) identified no other additional variants, after condition-
ing on the lead variant at the locus 3q28, 7p22.3, 10p12.31,
11q23.1, 12q23.3, 16q24.2, or 22q13.1.
Functional annotation. A large proportion of genome-wide
significant variants were intergenic (335/460) (Supplementary
Fig. 14). Variants with the highest probability of having a reg-
ulatory function based on RegulomeDB score (Category 1 Reg-
ulomeDB score) were located at 7p22.3 and at 22q13.1
(Supplementary Data 6). Of seven lead variants, four were
intergenic, four were in an active chromatin state and three
showed expression quantitative trait (eQTL) effects (Supple-
mentary Data 6). The lead SNP at 22q13.1 (rs4820299) was
associated with differential expression of the largest number of
genes (n= 6). In brain tissue, the alternate allele of this SNP was
associated with higher expression of TRIOBP suggesting that
higher expression was associated with smaller lateral ventricles
(Supplementary Fig. 15).
Partitioned heritability. SNP-based heritability in the sample of
European ancestry participants was estimated at 0.20 (SE= 0.02)
using LD score regression, and this was higher in women 0.19
(SE= 0.04) than in men 0.15 (SE= 0.05). The seven lead variants
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explained 1.5% of total variance in lateral ventricular volume.
Partitioning of heritability based on functional annotation using LD
score regression, revealed significant enrichment of SNPs within
500 bp of highly active enhancers, where 17% of SNPs accounted
for 54% of the heritability (p-value= 7.9 × 10−6, Supplementary
Table 2). Significant enrichment was also found for histone marks
including H3K27ac (which indicates enhancer and promoter
regions), H3K9ac (which highlights promoters), H3K4me3 (which
indicates promoters/transcription starts), and H3K4me1 (which
highlights enhancers) (Supplementary Table 2)25,26.
Functional enrichment analysis. Functional enrichment analysis
using regulatory regions from the ENCODE and Roadmap pro-
jects using the GWAS Analysis of Regulatory or Functional
Information Enrichment with LD correction (GARFIELD)
method revealed that SNPs associated with lateral ventricular
volume at p-value threshold <10−5 were more often located in
genomic regions harboring histone marks (H3K9ac (associated
with promoters) and H3K36me3 (associated with transcribed
regions))25 and DNaseI hypersensitivity sites (DHS) than a per-
muted background (Fig. 3, Supplementary Data 7).
Integration of gene expression data. Integration of functional
data from the Genotype-Tissues Expression (GTEx) project using
the MetaXcan method revealed two significant associations
between genetically predicted expression in brain tissue and lat-
eral ventricular volume (Supplementary Fig. 16). Expression
levels of TRIOBP at the locus 22q13.1 (p-value= 3.2 × 10−6) and
MRPS16 at the locus 10q22.2 (p-value= 1.8 × 10−6) were asso-
ciated with lateral ventricular volume.
Gene annotation and pathway analysis. The results of gene-
based and pathway analyses are illustrated in Supplementary
Table 3 and Supplementary Data 8. The pathway analysis
identified “regulation of cytoskeleton organization”
(GO:0051493) gene-set to be significantly enriched (p-value=
6 × 10−6). Genes of the “regulation of cytoskeleton organization”
pathway have previously been implicated in various neurological
or cardiovascular diseases (Supplementary Data 9). Furthermore,
pathways that pointed towards sphingosine 1 phosphate (S1P)
signaling showed suggestive enrichment (Supplementary Data 8).
Genetic correlation. Additionally, we examined the genetic
overlap between lateral ventricular volume and other traits
(Table 2). We found that genetically determined components of
thalamus and lateral ventricular volumes appear to be negatively
correlated (ρgenetic=−0.59, p-value= 3.14 × 10−6). This finding
was also confirmed at the phenotype level (Supplementary
Table 4). Weaker genetic overlap was observed with infant head
circumference (ρgenetic= 0.28, p-value= 8.7 × 10−3), intracranial
volume (ρgenetic= 0.35, p-value= 9 × 10−3), height (ρgenetic=
−0.14, p-value= 5.7 × 10−3), and mean pallidum (ρgenetic=
−0.29, p-value= 2.5 × 10−2), whereas no significant genetic
overlap was found with neurological diseases, psychiatric diseases,
or personality traits.
Genetic risk score. We next examined the association of genetic
risk scores (GRS) for Alzheimer’s disease, Parkinson’s disease,
schizophrenia, bipolar disorder, cerebral small vessel disease, and
tau-related pathology, including tau and phosphorylated tau
levels in cerebrospinal fluid, amyotrophic lateral sclerosis (ALS),
and progressive supranuclear palsy (PSP), using the lead SNPs
from the largest published GWA study and lateral ventricular
volume (Supplementary Data 10). We found a suggestive asso-
ciation of GRS for tau levels in cerebrospinal fluid (p-value=
9.59 × 10−3) and lateral ventricular volume (Supplementary
Table 5). The association was driven by one SNP (Supplementary
Table 1 Genome-wide significant results from the meta-analyses of lateral ventricular volume
SNP Chr Annotation Gene(s) A1/A2 Stage 1 Stage 2 Stage 3 combined
Zscore P Zscore P Zscore P
rs34113929a 3q28 intergenic SNAR-I,OSTN A/G −6.84 7.70E−12 −5.05 4.44E−07 −8.27 1.37E−16
rs9937293a 16q24.2 intergenic FOXL1,C16orf95 A/G 5.65 1.63E−08 5.61 2.03E−08 7.84 4.45E−15
7:2760334:C_CTa 7p22.3 intergenic AMZ1,GNA12 D/I −5.88 4.21E−09 −4.48 7.34E−06 −7.21 5.61E−13
rs12146713 12q23.3 intronic NUAK1 T/C −5.01 5.57E−07 −5.44 5.32E−08 −7.28 3.25E−13
rs4820299 22q13.1 intronic TRIOBP T/C −4.79 1.71E−06 -4.49 7.04E−06 −6.46 1.05E−10
rs35587371 10p12.31 intronic MLLT10 A/T −4.89 1.03E−06 −3.32 9.12E−04 −5.61 2.07E−08
rs7936534 11q23.1 intergenic ARHGAP20,C11orf53 A/G 4.25 2.12E−05 3.71 2.04E−04 5.54 2.96E−08
Variant that showed the lowest p-value in the fixed effect sample-size weighted Z-score meta-analysis for each locus is shown
SNP: single-nucleotide polymorphism, Chr: chromosome, A1/A2: effect allele/other allele, Freq: frequency of effect allele, Zscore: Z score from METAL, P: p-value
aVariants that surpassed genome-wide significance threshold in stage 1 meta-analysis; remaining SNPs listed in the table reached genome-wide significance threshold in combined, stage 3, meta-analysis
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Table 6). No association was observed with other examined
phenotypes (Supplementary Table 5).
Discussion
We have performed the first genome-wide association study of
lateral ventricular volume including up to 23,533 individuals. We
identified statistically significant association between lateral ven-
tricular volume and variants at 7 loci. Additionally, we found that
genetically determined components of thalamus and lateral ven-
tricular volume are correlated.
The strongest association was observed at the intergenic 3q28
locus between non-coding RNA SNAR-I and OSTN. This region
has previously been associated with cerebrospinal fluid tau/ptau
levels and Alzheimer’s disease risk, tangle pathology and cognitive
decline27. Similarly, the genome-wide significant locus at 12q23.3
encompasses NUAK1, which has also been associated with tau
pathology. Nuak1 modulates tau levels in human cells and animal
models and associates with tau accumulation in different tauo-
pathies28. NUAK1 is most prominently expressed in the brain
where it has a role in mediating axon growth and branching in
cortical neurons29. The lead SNP of the 12q23.3 locus mapped to
an intron of NUAK1. This SNP is among the top 1% of most
deleterious variants in the human genome based on its Combined
Annotation Dependent Depletion (CADD) score of 21.5 and is
located in an enhancer region (Supplementary Data 6). Interest-
ingly, this variant also showed an effect in early life.
In our data, the significant variants of 7p22.3 region had the
highest probability of being regulatory based on the RegulomeDB
score (1b). The lead variant at 7p22.3 was in an active chromatin
state and was associated with differential expression of GNA12
(Supplementary Data 6). The GNA12 gene is involved in various
transmembrane signaling systems30–33. Interestingly, this gene was
part of S1P signaling pathways identified to be enriched among
genes associated with lateral ventricular volume. S1P, a bioactive
sphingolipid metabolite, regulates nervous system development34
such as neuronal survival, neurite outgrowth, and axon
guidance35,36, and plays a role in neurotransmitter release37. It also
plays a role in regulating the development of germinal matrix (GM)
vasculature38. Disruption of S1P regulation results in defective
angiogenesis in GM, hemorrhage, and enlarged ventricles38.
The other identified locus, 16q24.2, has previously been
connected with small vessel disease and white-matter lesions
formation39. Further, the alternate allele of the lead SNP at
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22q13.1 in TRIOBP is associated with higher expression of the
same gene in basal ganglia and brain cortex, and the same allele
is associated with smaller lateral ventricular volume. Interest-
ingly, predicted expression of this gene in cerebral cortex was
significantly associated with lateral ventricular volume, sug-
gesting a causal functional role of the gene. The same analysis
revealed significant association of the expression of MRPS16 in
frontal cortex with lateral ventricular volume. This gene was
previously related to agenesis/hypoplasia of corpus callosum
and enlarged ventricles40.
Finally, the lead intergenic SNP at 11q23.1 maps between
C11orf53 and ARHGAP20, whereas the 10p12.31 region encom-
passes MLLT10 which has been linked to various leukemias,
ovarian cancer, and meningioma41,42. The effect size of this
variant on lateral ventricular volume was correlated with mean
cohort age, with the effect being near zero at younger age and
larger at older ages.
The gene-enrichment analysis highlighted “regulation of
cytoskeleton organization” (GO:0051493) pathway. Genes that
are part of this pathway have previously been implicated in
various neurological diseases such as Parkinson’s disease
(PARK2), frontotemporal dementia (MAPT), neurofibromatosis 2
(NF2), tuberous sclerosis (TSC1) (Supplementary Data 9). The
cytoskeleton is essentially involved in all cellular processes, and
therefore crucial for processes in the brain such as cell pro-
liferation, differentiation, migration, and signaling. Dysfunction
of cytoskeleton has been associated with neurodevelopmental,
psychiatric and neurodegenerative diseases43–45.
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Previous studies showed significant sex-specific differences in
lateral ventricular volume46,47. In our study we did not observe
sex-specific differences; as for the lead seven variants, both males
and females were contributing to the association signal. However,
we observed only one suggestive association at 4q35.2 that
showed association in men only. The lead variant (indel) is
mapped to FAT1 which encodes atypical cadherins. Mutation in
this gene causes a defect in cranial neural tube closure in a mouse
model and an increase in radial precursor proliferation in the
cortex48. However, the SNP-based heritability estimates were
slightly higher in females. This may be explained by the differ-
ences in sample size in male and female-specific analyses
implying that there is lower precision.
We estimated that 20% of genetic variance in lateral ven-
tricular volume could be explained by common genetic var-
iants, suggesting that common variants represent a substantial
fraction of overall genetic component of variance. Moreover,
the most statistically significant effect occurred in the regions of
highly active enhancers and histone marks, suggesting their
involvement in gene expression. Using the LD score regression
method, we found a significant negative genetic correlation
between lateral ventricular volume and thalamus volume.
However, these may not be independent events, but inverse
reflections of the same biology. Even though not strictly sig-
nificant, we also observed trends for genetic correlations with
other brain volumetric measures. Furthermore, no genome-
wide overlap was found between lateral ventricular volume and
various neurological or psychiatric diseases. Given that enlar-
gement of lateral ventricles has been suggested in Alzheimer’s
disease, we examined the association of APOE alleles and found
no association between the APOE ɛ4 (p-value= 0.86) or APOE
ɛ2 (p-value= 0.81) and lateral ventricular volume in our study
population.
As we identified loci underlying lateral ventricular volume at
the genome-wide level, but also genes and common pathways,
our results provide various insights into the genetic contribution
to lateral ventricular volume variability and a better under-
standing of the complex genetic architecture of brain structures.
The genes with variants that we found to be associated with
lateral ventricular volume are relevant to neurological aging
given the characteristics of the study population which is rela-
tively free from the disease as participants with stroke, traumatic
brain injury and dementia at the time of magnetic resonance
imaging (MRI) were excluded. This is in line with the previously
published work of Pfefferbaum et al. who showed that the sta-
bility of lateral ventricles is genetically determined, whereas other
factors such as normal aging or trauma and disease play a role in
its change1,16.
However, while studying genetic overlap of lateral ventricular
volume and various neurological or psychiatric disorders at
Table 2 The results of genetic correlation between the lateral ventricular volume and anthropometric traits, brain volumes,
neurological and psychiatric diseases and personality traits
Category Phenotype PMID N rg SE P
Anthropometric
Height 20881960 133,859 −0.135 0.049 5.70E−03
Infant head circumference 22504419 10,768 0.284 0.108 8.70E−03
Child birth length 25281659 28,459 −0.133 0.089 1.34E−01
Child birth weight 23202124 26,836 −0.118 0.102 2.47E−01
Brain volume
Mean thalamus 25607358 13,193 −0.591 0.127 3.14E−06
Mean pallidum 25607358 13,142 −0.29 0.129 2.47E−02
ICV 25607358 11,373 0.347 0.133 9.00E−03
Mean accumbens 25607358 13,112 −0.29 0.158 6.64E−02
Mean putamen 25607358 13,145 −0.15 0.089 9.13E−02
Mean hippocampus 25607358 13,163 −0.204 0.132 1.20E−01
Mean caudate 25607358 13,171 0.012 0.105 9.06E−01
Neurological diseases
Alzheimer’s disease 24162737 54,162 0.181 0.11 9.87E−02
Parkinson’s disease 19915575 5691 −0.096 0.084 2.55E−01
Amyotrophic lateral sclerosis 27455348 36,052 −0.032 0.128 8.04E−01
White matter hyperintensities 25663218 17,940 0.100 0.094 2.87E−01
Personality traits
Neo-conscientiousness 21173776 17,375 −0.359 0.158 2.27E−02
Neo-openness to experience 21173776 17,375 0.088 0.118 4.56E−01
Neuroticism 27089181 170,911 −0.03 0.065 6.45E−01
Psychiatric traits
ADHD 20732625 5422 −0.276 0.152 6.90E−02
PGC cross-disorder analysis 23453885 61,220 −0.121 0.071 8.65E−02
Major depressive disorder 22472876 18,759 −0.165 0.102 1.05E−01
Schizophrenia 25056061 77,096 −0.067 0.044 1.30E−01
Subjective well-being 27089181 298,420 0.087 0.075 2.50E−01
ADHD (no GC) 27663945 17,666 −0.151 0.149 3.11E−01
Depressive symptoms 27089181 161,460 −0.038 0.071 5.93E−01
Autism spectrum disorder 0 10,263 0.041 0.092 6.53E−01
Anorexia nervosa 24514567 17,767 0.011 0.056 8.43E−01
Bipolar disorder 21926972 16,731 0.009 0.078 9.12E−01
rg: genetic correlation, SE: standard error, P: p-value
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multiple levels (LD score regression/polygenic, GRS/oligogenic,
GWA hits/monogenic), we found evidence that some single
genetic variants have pleiotropic effect on lateral ventricular
volume and biochemical markers for a neurological disease (AD)
or meningioma (Supplementary Data 5), while no evidence was
found for genetic overlap with other neurological or psychiatric
disorders (Table 2, Supplementary Table 5). The pattern of
association between lateral ventricular volume and psychiatric
disorder, i.e., schizophrenia on multiple scales is similar to the
findings of Franke et al. who evaluated association of various
subcortical brain volumes and schizophrenia and reported no
evidence of genetic overlap49. Even though our study does not
provide a definite statement regarding the relationship between
lateral ventricular volume and neurological or psychiatric dis-
orders, it lays the foundation for future studies which should
disentangle whether lateral ventricular volume is genetically
related or unrelated to various neurological and psychiatric dis-
orders (e.g., result from reverse causation). Novel insights may be
revealed by improving the power of the studies, studying
homogeneous samples with harmonized phenotype assessment
methods along with evaluation of common and rare variants.
The strengths of our study are the large sample, population-
based design and the use of quantitative MRI. Our study also has
several limitations. Despite the effort to harmonize phenotype
assessment, the methods used to quantify lateral ventricular
volume differ across cohorts. Because of this phenotypic hetero-
geneity, association results of participating cohorts were com-
bined using a sample-size weighted meta-analysis, thus limiting
discussion on effect sizes. Secondly, phenotypic heterogeneity
may have caused the loss of statistical power. However, despite
heterogeneity in the phenotype assessment, the association signals
were coming from several studies irrespective of the method of
phenotype assessment, which suggests robustness of our findings.
Furthermore, although we made an effort to include cohorts of
EA and AA ancestry, the study comprised predominately of
individuals of European origin (22,045 individuals of EA and
1488 of AA ancestry). Given the disparity in sample size, it is
difficult to distinguish whether any inconsistency in results
between the two groups stems from true genetic differences or
from differential power to detect genetic effects. Indeed, this is
also exemplified by the plots of the Z-scores (Supplementary
Fig. 11) showing that direction of effect size in AA cohorts is
often inconsistent with the direction of effect size in EA cohorts.
However, the same inconsistency can be observed with European
cohorts of equally small sample size. This inconsistency may be
due to small sample size rather than ethnic background but we
cannot rule out that racial-ethnic specific effects may exit. This
limitation underscores the need for expanding research studies in
non-European populations. Finally, as some loci only reached the
genome-wide significance in the combined meta-analysis, they
should be considered as highly probable findings and would still
require independent replication.
To conclude, we identified genetic associations of lateral ven-
tricular volume with variants mapping to 7 loci and implicating
several pathways, including pathway related to tau pathology,
cytoskeleton organization, and S1P signaling. These data provide
new insights into understanding brain morphology.
Methods
Study design. The overview of study design is illustrated in Supplementary Fig. 1.
We performed a GWA meta-analysis of 11,396 participants of mainly European
ancestry from 12 studies (stage 1) that contributed summary statistic data before a
certain deadline. The deadline was set prior to data inspection and was not
influenced by the results of the GWA meta-analysis. Variants that surpassed the
genome-wide significance threshold (p-value < 5 × 10−8) were subsequently eval-
uated in an independent sample of 12,137 participants of mainly European
ancestry from 14 studies (stage 2). Finally, we performed a meta-analysis of all
stage 1 and stage 2 studies (stage 3).
Study population. All participating studies are part of the Cohorts for Heart and
Aging Research in Genomic Epidemiology (CHARGE) consortium50. A detailed
description of participating studies can be found in Supplementary Note 1. General
characteristics of study participants are provided in Supplementary Data 1. Written
informed consent was obtained from all participants. Each study was approved by
local ethical committees or the institutional review boards (see Supplementary
Note 1 for details).
Imaging. Each study performed MRI and estimated the volume of the lateral
ventricles and intracranial volume (ICV). The field strength of scanners ranged
from 0.35 to 3 T. Information on scanner manufacturers and measurement
methods is provided in Supplementary Data 2. While most of the studies quantified
lateral ventricular volume using validated automated segmentation methods, some
studies used validated visual grading scales. The visual and volumetric scales were
compared previously and showed high agreement for lateral ventricular volume2.
The assessment of consistency of lateral ventricular volume on volumetric scale
across time and different versions of software (freesurfer v4.5, v5.1, and v6.0),
revealed high intraclass correlation (ICC > 0.98) in a subset of participants from the
Rotterdam Study. Participants with dementia at the time of MRI, traumatic brain
injury, prior or current stroke or intracranial tumors were excluded.
Genotyping and imputation. Information on genotyping platforms, quality con-
trol procedures and imputations methods for each participating study are provided
in Supplementary Data 3. All studies used commercially available genotyping
arrays, including Illumina or Affymetrix arrays. Similar quality control procedures
were applied for each study (Supplementary Data 3). Using the validated software
(Minimac51, IMPUTE52, BEAGLE53), each study performed genotype imputations
using mostly the 1000 Genome phase 1 v3 reference panel.
Genome-wide association (GWA) analysis. Each participating study performed
the GWA analysis of total lateral ventricular volume under an additive model
using variant allele dosage as predictors and natural logarithm of the total lateral
ventricular volume as the dependent variable. Transformation of the lateral
ventricular volume was applied to obtain approximately normal distribution
(Supplementary Fig. 17). The association analyses were adjusted for age, sex,
total intracranial volume, age2 if significant, population stratification, familial
relationship (family-based studies) or study site (multi-site studies). Population
stratification was controlled for by including principal components derived from
genome-wide genotype data. Study-specific details on covariates and software
used are provided in Supplementary Data 3. Quality control (QC) was conducted
for all participating studies using a standardized protocol provided by Winkler
et al.54. Variants with low imputation quality r2 < 0.3 or minor allele count
(MAC) ≤ 6 were filtered out. The association results of participating studies were
combined using a fixed-effect sample-size weighted Z-score meta-analysis in
METAL because of the difference in measurement methods of lateral ventricular
volume55. Genomic control was applied to account for small amounts of
population stratification or unaccounted relatedness. After the meta-analysis,
variants with information in less than half the total sample size were excluded.
Meta-analyses were performed separately for each of the stages. In the stage 1
meta-analysis, a p-value < 5 × 10−8 was considered significant. Variants that
surpassed the threshold were evaluated in the stage 2 meta-analysis. In order to
model linkage disequilibrium (LD) between those variants, we first calculated the
number of independent tests using the eigenvalues of a correlation matrix using
the Matrix Spectral Decomposition (matSpDlite) software56. Subsequently, a
Bonferroni correction was applied for the effective number of independent tests
(0.05/10 independent SNPs= 5 × 10−3). Additionally, all analyses were stratified
by sex. Following the same QC steps as for overall analyses, the sex-stratified
association results of participating studies were combined using a fixed-effect
sample-size weighted Z-score meta-analysis in METAL while applying genomic
control55. The variants were assessed only if test statistics (Z-score) were het-
erogeneous between males and females (p-value < 0.1) and if the association in a
sex-combined analysis did not reach genome-wide significance threshold57.
Conditional analysis. In order to identify variants that were independently asso-
ciated with lateral ventricular volume, we performed conditional and joint (COJO)
GWA analysis using Genome-wide Complex Trait Analysis (GCTA), version
1.26.058. LD pattern was calculated based on 1000 Genome phase 1v3 imputed data
of 6291 individuals from the Rotterdam Study I.
Functional annotation. To annotate genome-wide significant variants with reg-
ulatory information, we used HaploReg v4.159, RegulomeDB v1.160, and Combined
Annotation Dependent Depletion (CADD) tools61. To determine whether they
have an effect on gene expression, we used GTEx data62. For the lead variants, we
explored 5 chromatin marks assayed in 127 epigenomes (H3K4me3, H3K4me1,
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H3K36me3, H3K27me3, H3K9me3) of RoadMap data63. To search for pleiotropic
associations between our lead variants and their proxies (r2 > 0.7) with other traits,
we used the PhenoScanner database designed to facilitate the cross-referencing of
genetic variants with many phenotypes9. The association results with genome-wide
significance at 5 × 10−8 were extracted.
Variance explained. The proportion of variance in lateral ventricular volume
explained by each lead variant was calculated using Pearson’s phi coefficient
squared as explained in Draisma et al.64. The total proportion of variance in lateral
ventricular volume was calculated by adding up the proportions of variance in
lateral ventricular volume explained by each lead association signal.
Partitioned heritability. SNP-based heritability and partitioned heritability ana-
lyses were performed using LD score regression following the previously described
method65. Partitioned heritability analysis determines enrichment of heritability in
SNPs partitioned into 24 functional classes as reported in Finucane et al.65. To
avoid bias, an additional 500 bp window was included around the variants included
in the functional classes. Only the HapMap3 variants were included as these seem
to be well-imputed across cohorts.
Functional enrichment analysis. We performed functional enrichment analysis
using regulatory regions from the ENCODE and Roadmap projects using GWAS
Analysis of Regulatory or Functional Information Enrichment with LD correction
(GARFIELD) method66. The method provides fold enrichment (FE) statistics at
various GWA p-value thresholds after taking into account LD, minor allele fre-
quency, and local gene density66. The FE statistics were calculated at eight GWA
p-value thresholds (0.1 to 1 × 10−8). The associations were tested for various reg-
ulatory elements including DNase-I hypersensitivity sites, histone modifications,
chromatin states and transcription factor binding sites in over 1000 cell and tissue-
specific annotations66. The significance threshold calculated based on the number
of annotations used was set at 4.97 × 10−5.
Integration of gene expression. To integrate functional data in the context of our
meta-analysis results, we used the MetaXcan method, which evaluated the asso-
ciation between lateral ventricular volume and brain-specific gene-expression levels
predicted by genetic variants using the data from GTEx project62,67. This method is
an extension of PrediXcan method modified to use summary statistic data from
meta-analysis67. Based on a total number of genes tested, the Bonferroni-corrected
significance threshold was set to 0.05/12,379= 4 × 10−6.
Gene annotation and pathway-based analysis. The gene-based test statistics
were computed using VEGAS2 software which tests for enrichment of multiple
single variants within the genes while accounting for LD structure68. LD structure
was computed based on the 1000 Genomes phase 3 population. Variants within
10 kb of the 5′ and 3′ untranslated regions were included in this analysis in order to
maintain regulatory variants68. Subsequently, the gene-based scores were used to
perform gene-set enrichment analysis using VEGAS2pathway69. VEGAS2Pathway
approach accounts for LD between variants within a gene, and between neigh-
boring genes, gene size, and pathway size69. It uses computationally predicted Gene
Ontology pathways and curated gene-sets from the MSigDB, PANTHER, and
pathway commons databases69. The pathway-based significance threshold was set
to the p-value= 1 × 10−5 while taking into account the multiple testing of corre-
lated pathways (0.05/5000 independent tests)69.
Genetic correlation. We used the LD score regression method to estimate genetic
correlations between lateral ventricular volume and various traits including
anthropometric traits, brain volumes, neurological and psychiatric diseases and
personality traits. The analyses were performed using a centralized database of
summary-level GWA study results and a web interface for LD score regression, the
LD-hub70. Summary-level GWA study results for white matter hyperintensities
were obtained from the CHARGE consortium71 and the analyses were performed
using the ldsc tool (https://github.com/bulik/ldsc).
Genetic risk scores. We generated genetic risk scores (GRS) for Alzheimer’s
disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, bipolar dis-
order, schizophrenia, white matter lesions and tau-related phenotypes. The tau-
related phenotypes, including tau and phosphorylated tau levels in cerebrospinal
fluid, and progressive supranuclear palsy (PSP), were studied in relatively small
sample and are therefore not appropriate for LD score regression. We extracted
the lead genome-wide significantly associated SNPs and their effect estimates
from the largest published GWA studies (Supplementary Data 10). For white
matter lesions burden, effect estimate and standard errors were estimated from
Z-statistics using the previously published formula72. The allele associated with
an increased risk in corresponding traits was considered to be the effect allele.
The weighted GRS was constructed as the sum of products of effect sizes as
weights and respective allele dosages from 1000 Genome imputed data of Rot-
terdam Study using R software version 3.2.5 (https://www.R-project.org). Var-
iants with low imputation quality (r2 < 0.3) were excluded. Subsequently, the
GRS was tested for association with lateral ventricular volume in three cohorts of
Rotterdam Study while adjusting for age, sex, total intracranial volume, age2 and
population stratification. The significance threshold for genetic risk score
association was set to p-value= 5 × 10−3 (0.05/10) based on the number of
genetic risk scores tested.
Data availability
The summary statistics will be made available upon publication on the CHARGE dbGaP
site under the accession number phs000930.v7.p1.
Received: 25 October 2017 Accepted: 8 August 2018
References
1. Pfefferbaum, A., Sullivan, E. V. & Carmelli, D. Morphological changes in aging
brain structures are differentially affected by time-linked environmental
influences despite strong genetic stability. Neurobiol. Aging 25, 175–183
(2004).
2. Carmichael, O. T. et al. Ventricular volume and dementia progression in
the Cardiovascular Health Study. Neurobiol. Aging 28, 389–397
(2007).
3. Apostolova, L. G. et al. Hippocampal atrophy and ventricular enlargement in
normal aging, mild cognitive impairment (MCI), and Alzheimer Disease.
Alzheimer Dis. Assoc. Disord. 26, 17–27 (2012).
4. Long, X. et al. Healthy aging: an automatic analysis of global and regional
morphological alterations of human brain. Acad. Radiol. 19, 785–793 (2012).
5. Nestor, S. M. et al. Ventricular enlargement as a possible measure of
Alzheimer’s disease progression validated using the Alzheimer’s disease
neuroimaging initiative database. Brain 131, 2443–2454 (2008).
6. Kuller, L. H. et al. Determinants of vascular dementia in the Cardiovascular
Health Cognition Study. Neurology 64, 1548–1552 (2005).
7. Mak, E. et al. Longitudinal whole-brain atrophy and ventricular enlargement
in nondemented Parkinson’s disease. Neurobiol. Aging 55, 78–90 (2017).
8. Kuller, L. H., Lopez, O. L., Becker, J. T., Chang, Y. & Newman, A. B. Risk of
dementia and death in the long-term follow-up of the Pittsburgh
Cardiovascular Health Study-Cognition Study. Alzheimers Dement. 12,
170–183 (2016).
9. Vita, A., De Peri, L., Silenzi, C. & Dieci, M. Brain morphology in first-episode
schizophrenia: a meta-analysis of quantitative magnetic resonance imaging
studies. Schizophr. Res. 82, 75–88 (2006).
10. Kempton, M. J., Geddes, J. R., Ettinger, U., Williams, S. C. & Grasby, P. M.
Meta-analysis, database, and meta-regression of 98 structural imaging studies
in bipolar disorder. Arch. Gen. Psychiatry 65, 1017–1032 (2008).
11. Olabi, B. et al. Are there progressive brain changes in schizophrenia? A meta-
analysis of structural magnetic resonance imaging studies. Biol. Psychiatry 70,
88–96 (2011).
12. Mosley, T. H. Jr. et al. Cerebral MRI findings and cognitive functioning: the
Atherosclerosis Risk in Communities study. Neurology 64, 2056–2062 (2005).
13. Appelman, A. P. et al. White matter lesions and lacunar infarcts are
independently and differently associated with brain atrophy: the SMART-MR
study. Cerebrovasc. Dis. 29, 28–35 (2010).
14. Geerlings, M. I. et al. Brain volumes and cerebrovascular lesions on MRI in
patients with atherosclerotic disease. The SMART-MR study. Atherosclerosis
210, 130–136 (2010).
15. Horga, G. et al. Correlations between ventricular enlargement and gray and
white matter volumes of cortex, thalamus, striatum, and internal capsule in
schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci. 261, 467–476 (2011).
16. Kremen, W. S. et al. Heritability of brain ventricle volume: converging
evidence from inconsistent results. Neurobiol. Aging 33, 1–8 (2012).
17. Peper, J. S., Brouwer, R. M., Boomsma, D. I., Kahn, R. S. & Hulshoff Pol, H. E.
Genetic influences on human brain structure: a review of brain imaging
studies in twins. Hum. Brain Mapp. 28, 464–473 (2007).
18. Schmitt, J. E. et al. Review of twin and family studies on neuroanatomic
phenotypes and typical neurodevelopment. Twin. Res. Hum. Genet. 10,
683–694 (2007).
19. Kremen, W. S. et al. Genetic and environmental influences on the size of
specific brain regions in midlife: the VETSA MRI study. Neuroimage 49,
1213–1223 (2010).
20. Eyler, L. T. et al. Genetic patterns of correlation among subcortical volumes in
humans: results from a magnetic resonance imaging twin study. Hum. Brain.
Mapp. 32, 641–653 (2011).
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06234-w
8 NATURE COMMUNICATIONS |  (2018) 9:3945 | DOI: 10.1038/s41467-018-06234-w |www.nature.com/naturecommunications
21. Mata, I. et al. A neuregulin 1 variant is associated with increased lateral
ventricle volume in patients with first-episode schizophrenia. Biol. Psychiatry
65, 535–540 (2009).
22. Crespo-Facorro, B. et al. Low-activity allele of Catechol-O-Methyltransferase
(COMTL) is associated with increased lateral ventricles in patients with first
episode non-affective psychosis. Prog. Neuro-Psychoph 31, 1514–1518
(2007).
23. Skol, A. D., Scott, L. J., Abecasis, G. R. & Boehnke, M. Joint analysis is more
efficient than replication-based analysis for two-stage genome-wide
association studies. Nat. Genet. 38, 209–213 (2006).
24. Staley, J. R. et al. PhenoScanner: a database of human genotype-phenotype
associations. Bioinformatics 32, 3207–3209 (2016).
25. Consortium, E. P. An integrated encyclopedia of DNA elements in the human
genome. Nature 489, 57–74 (2012).
26. Roadmap Epigenomics, C. et al. Integrative analysis of 111 reference human
epigenomes. Nature 518, 317–330 (2015).
27. Cruchaga, C. et al. GWAS of cerebrospinal fluid tau levels identifies risk
variants for Alzheimer’s disease. Neuron 78, 256–268 (2013).
28. Lasagna-Reeves, C. A. et al. Reduction of Nuak1 decreases tau and reverses
phenotypes in a tauopathy mouse model. Neuron 92, 407–418 (2016).
29. Courchet, J. et al. Terminal axon branching is regulated by the LKB1-NUAK1
kinase pathway via presynaptic mitochondrial capture. Cell 153, 1510–1525
(2013).
30. Yanamadala, V., Negoro, H., Gunaratnam, L., Kong, T. & Denker, B. M.
Galpha12 stimulates apoptosis in epithelial cells through JNK1-mediated Bcl-2
degradation and up-regulation of IkappaBalpha. J. Biol. Chem. 282,
24352–24363 (2007).
31. Kelly, P. et al. The G12 family of heterotrimeric G proteins promotes breast
cancer invasion and metastasis. Proc. Natl Acad. Sci. USA 103, 8173–8178
(2006).
32. Krakstad, B. F., Ardawatia, V. V. & Aragay, A. M. A role for Galpha12/
Galpha13 in p120ctn regulation. Proc. Natl Acad. Sci. USA 101, 10314–10319
(2004).
33. Zhu, D., Kosik, K. S., Meigs, T. E., Yanamadala, V. & Denker, B. M. Galpha12
directly interacts with PP2A: evidence FOR Galpha12-stimulated PP2A
phosphatase activity and dephosphorylation of microtubule-associated
protein, tau. J. Biol. Chem. 279, 54983–54986 (2004).
34. Blaho, V. A. & Hla, T. An update on the biology of sphingosine 1-phosphate
receptors. J. Lipid Res. 55, 1596–1608 (2014).
35. Strochlic, L., Dwivedy, A., van Horck, F. P., Falk, J. & Holt, C. E. A role for S1P
signalling in axon guidance in the Xenopus visual system. Development 135,
333–342 (2008).
36. Herr, D. R. et al. Sphingosine 1-phosphate (S1P) signaling is required for
maintenance of hair cells mainly via activation of S1P2. J. Neurosci. 27,
1474–1478 (2007).
37. Shen, H. et al. Coupling between endocytosis and sphingosine kinase 1
recruitment. Nat. Cell Biol. 16, 652–662 (2014).
38. Ma, S., Santhosh, D., Kumar, T. P. & Huang, Z. A brain-region-specific neural
pathway regulating germinal matrix angiogenesis. Dev. Cell 41, 366–381
(2017).
39. Traylor, M. et al. Genetic variation at 16q24.2 is associated with small vessel
stroke. Ann. Neurol. 81, 383–394 (2017).
40. Miller, C. et al. Defective mitochondrial translation caused by a ribosomal
protein (MRPS16) mutation. Ann. Neurol. 56, 734–738 (2004).
41. Pharoah, P. D. P. et al. GWAS meta-analysis and replication identifies three
new susceptibility loci for ovarian cancer. Nat. Genet. 45, 362–370 (2013).
42. Egan, K. M. et al. Brain tumor risk according to germ-line variation in the
MLLT10 locus. Eur. J. Hum. Genet. 23, 132–134 (2015).
43. Paus, T., Pesaresi, M. & French, L. White matter as a transport system.
Neuroscience 276, 117–125 (2014).
44. McMurray, C. T. Neurodegeneration: diseases of the cytoskeleton? Cell Death
Differ. 7, 861–865 (2000).
45. Cairns, N. J., Lee, V. M. & Trojanowski, J. Q. The cytoskeleton in
neurodegenerative diseases. J. Pathol. 204, 438–449 (2004).
46. Hasan, K. M., Moeller, F. G. & Narayana, P. A. DTI-based segmentation and
quantification of human brain lateral ventricular CSF volumetry and mean
diffusivity: validation, age, gender effects and biophysical implications. Magn.
Reson. Imaging 32, 405–412 (2014).
47. Pfefferbaum, A. et al. Variation in longitudinal trajectories of regional brain
volumes of healthy men and women (ages 10 to 85 years) measured with atlas-
based parcellation of MRI. Neuroimage 65, 176–193 (2013).
48. Badouel, C. et al. Fat1 interacts with Fat4 to regulate neural tube closure,
neural progenitor proliferation and apical constriction during mouse brain
development. Development 142, 2781–2791 (2015).
49. Franke, B. et al. Genetic influences on schizophrenia and subcortical brain
volumes: large-scale proof of concept. Nat. Neurosci. 19, 420–431 (2016).
50. Psaty, B. M. et al. Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) Consortium: design of prospective meta-analyses of
genome-wide association studies from 5 cohorts. Circ. Cardiovasc. Genet. 2,
73–80 (2009).
51. Howie, B., Fuchsberger, C., Stephens, M., Marchini, J. & Abecasis, G. R. Fast
and accurate genotype imputation in genome-wide association studies
through pre-phasing. Nat. Genet. 44, 955–959 (2012).
52. Howie, B. N., Donnelly, P. & Marchini, J. A flexible and accurate genotype
imputation method for the next generation of genome-wide association
studies. PLoS Genet. 5, e1000529 (2009).
53. Browning, S. R. & Browning, B. L. Rapid and accurate haplotype phasing and
missing-data inference for whole-genome association studies by use of
localized haplotype clustering. Am. J. Hum. Genet. 81, 1084–1097 (2007).
54. Winkler, T. W. et al. Quality control and conduct of genome-wide association
meta-analyses. Nat. Protoc. 9, 1192–1212 (2014).
55. Willer, C. J., Li, Y. & Abecasis, G. R. METAL: fast and efficient meta-analysis
of genomewide association scans. Bioinformatics 26, 2190–2191 (2010).
56. Li, J. & Ji, L. Adjusting multiple testing in multilocus analyses using the
eigenvalues of a correlation matrix. Heredity 95, 221–227 (2005).
57. Zeggini, E. & Ioannidis, J. P. Meta-analysis in genome-wide association
studies. Pharmacogenomics 10, 191–201 (2009).
58. Yang, J., Lee, S. H., Goddard, M. E. & Visscher, P. M. GCTA: a tool for
genome-wide complex trait analysis. Am. J. Hum. Genet. 88, 76–82 (2011).
59. Ward, L. D. & Kellis, M. HaploReg: a resource for exploring chromatin states,
conservation, and regulatory motif alterations within sets of genetically linked
variants. Nucleic Acids Res. 40, D930–D934 (2012).
60. Boyle, A. P. et al. Annotation of functional variation in personal genomes
using RegulomeDB. Genome Res. 22, 1790–1797 (2012).
61. Kircher, M. et al. A general framework for estimating the relative
pathogenicity of human genetic variants. Nat. Genet. 46, 310–315 (2014).
62. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat.
Genet. 45, 580–585 (2013).
63. Ernst, J. & Kellis, M. ChromHMM: automating chromatin-state discovery and
characterization. Nat. Methods 9, 215–216 (2012).
64. Draisma, H. H. M. et al. Genome-wide association study identifies novel
genetic variants contributing to variation in blood metabolite levels. Nat.
Commun. 6, 7208 (2015).
65. Finucane, H. K. et al. Partitioning heritability by functional annotation using
genome-wide association summary statistics. Nat. Genet. 47, 1228 (2015).
66. Iotchkova, V. et al. GARFIELD - GWAS Analysis of Regulatory or Functional
Information Enrichment with LD correction. Preprint at https://www.biorxiv.
org/content/early/2016/11/07/085738 (2016).
67. Barbeira, A., et al. MetaXcan: summary statistics based gene-level association
method infers accurate PrediXcan results. Preprint at https://www.biorxiv.org/
content/early/2016/03/23/045260 (2016).
68. Mishra, A. & Macgregor, S. VEGAS2: software for more flexible gene-based
testing. Twin. Res. Hum. Genet. 18, 86–91 (2015).
69. Mishra, A. & MacGregor, S. A novel approach for pathway analysis of GWAS
data highlights role of BMP signaling and muscle cell differentiation in
colorectal cancer susceptibility. Twin. Res. Hum. Genet. 20, 1–9 (2017).
70. Zheng, J. et al. LD Hub: a centralized database and web interface to perform
LD score regression that maximizes the potential of summary level GWAS
data for SNP heritability and genetic correlation analysis. Bioinformatics 33,
272–279 (2017).
71. Verhaaren, B. F. et al. Multiethnic genome-wide association study of cerebral
white matter hyperintensities on MRI. Circ. Cardiovasc Genet 8, 398–409
(2015).
72. Chauhan, G. et al. Association of Alzheimer’s disease GWAS loci with MRI
markers of brain aging. Neurobiol. Aging 36, 1765.e7–1765.e16 (2015).
Acknowledgements
See Supplementary Note 2 for information on funding sources.
Author contributions
Conceived the study and drafted the manuscript: D.V., H.H.A., M.A.I., S.S., M.F. Per-
formed statistical analyses: D.V., H.H.A., X.J., Q.Y., A.V.S., J.C.B., A.T., M.S., N.J.A., E.H.,
Y.S., M.L., M.B., S.T., J.Y., N.A.G., M.S.P., S.J.L., A.N., L.R.Y., and S.L. Acquired data:
O.A.A., D.A., N.A., K.A., M.B., D.M.B., A.B., F.B., H.B., R.N.B., R.B., A.M.D., P.L.J., I.J.D.,
C.D., D.A.F., R.F.G., J.G., V.G., T.B.H., G.H., D.S.K., J.B.K., C.E.L., M.L., W.T.L., O.L.L.,
P.M., P.A.N., H.M., K.A.M., T.H.M., R.M., M.N., M.S.P., Z.P., B.M.P., K.R., C.L.S., R.S.,
P.S.S., P.J.S., S.S.S., D.J.S., A.T., A.G.U., M.C.V.H., M.W.V., W.W., T.W., A.V.W., K.W.,
M.J.W., H.T., W.K., D.A.B., J.W. J., T.P., J.A.W., H.S., P.S.S., A.V., H.J.G., J.I.R., C.M.D.,
L.J.L., S.S., M.A.I., M.F. All authors critically reviewed the manuscript for important
intellectual content.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
018-06234-w.
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06234-w ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:3945 | DOI: 10.1038/s41467-018-06234-w |www.nature.com/naturecommunications 9
Competing interests: A.M.D. is a Founder of and holds equity in CorTechs Labs, Inc,
and serves on its Scientific Advisory Board. He is a member of the Scientific Advisory
Board of Human Longevity, Inc. and receives funding through research agreements with
General Electric Healthcare and Medtronic, Inc. The terms of these arrangements have
been reviewed and approved by UCSD in accordance with its conflict of interest policies.
The remaining authors declare no competing interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2018
Dina Vojinovic1, Hieab H. Adams 1,2, Xueqiu Jian3, Qiong Yang 4, Albert Vernon Smith 5,6, Joshua C. Bis7,
Alexander Teumer 8, Markus Scholz 9,10, Nicola J. Armstrong11,12, Edith Hofer13,14, Yasaman Saba15,
Michelle Luciano 16, Manon Bernard17, Stella Trompet18,19, Jingyun Yang20,21, Nathan A. Gillespie22,
Sven J. van der Lee 1, Alexander Neumann 23, Shahzad Ahmad1, Ole A. Andreassen 24, David Ames25,26,
Najaf Amin1, Konstantinos Arfanakis20,27,28, Mark E. Bastin16,29,30, Diane M. Becker31, Alexa S. Beiser4,
Frauke Beyer32, Henry Brodaty 12,33, R. Nick Bryan34, Robin Bülow35, Anders M. Dale36,
Philip L. De Jager 37,38, Ian J. Deary16, Charles DeCarli39, Debra A. Fleischman20,21,40, Rebecca F. Gottesman41,
Jeroen van der Grond42, Vilmundur Gudnason 5,6, Tamara B. Harris43, Georg Homuth44, David S. Knopman45,
John B. Kwok46,47, Cora E. Lewis48, Shuo Li 4, Markus Loeffler9,10, Oscar L. Lopez49, Pauline Maillard39,
Hanan El Marroun23,50, Karen A. Mather12,51, Thomas H. Mosley52, Ryan L. Muetzel1,23, Matthias Nauck53,
Paul A. Nyquist41, Matthew S. Panizzon54, Zdenka Pausova17,55, Bruce M. Psaty7,56,57,58, Ken Rice59,
Jerome I. Rotter60,61, Natalie Royle16,29,30, Claudia L. Satizabal 62,63, Reinhold Schmidt13,
Peter R. Schofield 46,51, Pamela J. Schreiner64, Stephen Sidney65, David J. Stott66, Anbupalam Thalamuthu12,
Andre G. Uitterlinden67, Maria C. Valdés Hernández16,29,30, Meike W. Vernooij1,2, Wei Wen12, Tonya White2,23,
A. Veronica Witte32,68, Katharina Wittfeld69, Margaret J. Wright 70, Lisa R. Yanek31, Henning Tiemeier 23,71,
William S. Kremen54, David A. Bennett20,21, J. Wouter Jukema19,72, Tomas Paus73,74,
Joanna M. Wardlaw 16,29,30, Helena Schmidt15, Perminder S. Sachdev 12,75, Arno Villringer32,68,
Hans Jörgen Grabe 69,76, W T Longstreth56,77, Cornelia M. van Duijn1,78, Lenore J. Launer43,
Sudha Seshadri62,63, M Arfan Ikram 1,2,79 & Myriam Fornage3
1Department of Epidemiology, Erasmus MC University Medical Center, Rotterdam 3015 CN, The Netherlands. 2Department of Radiology and
Nuclear Medicine, Erasmus MC University Medical Center, Rotterdam 3015 CN, The Netherlands. 3The University of Texas Health Science Center
at Houston Institute of Molecular Medicine, Houston, TX 77030, USA. 4Department of Biostatistics, School of Public Health, Boston University,
Boston, MA 02118, USA. 5Icelandic Heart Association, Kopavogur 201, Iceland. 6Faculty of Medicine, University of Iceland, Reykjavik 101, Iceland.
7Cardiovascular Health Research Unit, Department of Medicine, University of Washington, Seattle, WA 98101, USA. 8Institute for Community
Medicine, University Medicine Greifswald, Greifswald 17475, Germany. 9Institute for Medical Informatics, Statistics and Epidemiology, University of
Leipzig, Leipzig 04107, Germany. 10LIFE Research Center for Civilization Diseases, University of Leipzig, Leipzig 04103, Germany. 11Mathematics
and Statistics, Murdoch University, Perth, WA 6150, Australia. 12Centre for Healthy Brain Ageing, School of Psychiatry, UNSW, Sydney, NSW 2052,
Australia. 13Clinical Division of Neurogeriatrics, Department of Neurology, Medical University of Graz, Graz 8036, Austria. 14Institute for Medical
Informatics, Statistics and Documentation, Medical University of Graz, Graz 8036, Austria. 15Gottfried Schatz research center, Institute for
Molecular biology and biochemistry, Graz 8010, Austria. 16Centre for Cognitive Ageing and Cognitive Epidemiology, Psychology, University of
Edinburgh, Edinburgh EH8 9JZ, UK. 17Research Institute of the Hospital for Sick Children, Toronto, Ontario M5G 1X8, Canada. 18Section of
Gerontology and Geriatrics, Department of Internal Medicine, Leiden University Medical Center, Leiden 2300 RC, The Netherlands. 19Department
of Cardiology, Leiden University Medical Center, Leiden 2300 RC, The Netherlands. 20Rush Alzheimer’s Disease Center, Rush University Medical
Center, Chicago, IL 60612, USA. 21Department of Neurological Sciences, Rush University Medical Center, Chicago, IL 60612, USA. 22Virginia
Institute for Psychiatric and Behavioral Genetics, Virginia Commonwealth University, Richmond, VA 23284, USA. 23Department of Child and
Adolescent Psychiatry/ Psychology, Erasmus University Medical Center Rotterdam, Rotterdam 3000 CB, The Netherlands. 24Norwegian Centre for
Mental Disorders Research (NORMENT), Institute of Clinical Medicine, University of Oslo, Oslo 0372, Norway. 25National Ageing Research
Institute, Melbourne, VIC 3052, Australia. 26Academic Unit for Psychiatry of Old Age, University of Melbourne, Melbourne, VIC 3101, Australia.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06234-w
10 NATURE COMMUNICATIONS |  (2018) 9:3945 | DOI: 10.1038/s41467-018-06234-w |www.nature.com/naturecommunications
27Department of Biomedical Engineering, Illinois Institute of Technology, Chicago, IL 60616, USA. 28Department of Diagnostic Radiology and
Nuclear Medicine, Rush University Medical Center, Chicago, IL 60612, USA. 29Centre for Clinical Brain Sciences, University of Edinburgh & Brain
Research Imaging Centre, University of Edinburgh, Edinburgh EH16 4SB, UK. 30Division of Neuroimaging Sciences, Brain Research Imaging Centre,
University of Edinburgh, Edinburgh EH16 4SB, UK. 31Division of General Internal Medicine, Department of Medicine, Johns Hopkins School of
Medicine, Baltimore, MD 21287, USA. 32Department of Neurology, Max Planck Institute of Cognitive and Brain Sciences, Leipzig 04103, Germany.
33Dementia Collaborative Research Centre – Assessment and Better Care, University of New South Wales, Sydney, NSW 2031, Australia. 34The
University of Texas at Austin Dell Medical School, Austin, TX 78705, USA. 35Institute for Diagnostic Radiology and Neuroradiology, University
Medicine Greifswald, Greifswald 17475, Germany. 36Department of Cognitive Science, University of California, San Diego, La Jolla, CA 92093, USA.
37Center for Translational and Computational Neuroimmunology, Department of Neurology, Columbia University Medical Center, New York, NY
10032, USA. 38Cell Circuits Program, Broad Institute, Cambridge, MA 02142, USA. 39Department of Neurology and Center for Neuroscience,
University of California, Davis, CA 95817, USA. 40Department of Behavioral Sciences, Rush University Medical Center, Chicago, IL 60612, USA.
41Department of Neurology, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA. 42Department of Radiology, Leiden University Medical
Center, Leiden 2300 RC, The Netherlands. 43Laboratory of Epidemiology and Population Sciences, National Institute on Aging, Intramural Research
Program, National Institutes of Health, Bethesda, MD 20892, USA. 44Interfaculty Institute for Genetics and Functional Genomics, University
Medicine Greifswald, Greifswald 17475, Germany. 45Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA. 46School of Medical
Sciences, University of New South Wales, Sydney, NSW 2052, Australia. 47Brain and Mind Centre, The University of Sydney, Camperdown, NSW
2050, Australia. 48The University of Alabama at Birmingham School of Medicine, Birmingham, AL 35294, USA. 49Department of Neurology,
University of Pittsburgh, Pittsburgh, PA 15213, USA. 50Department of Psychology, Education and Child Studies, Erasmus University Rotterdam,
Rotterdam, 3062 PA, The Netherlands. 51Neuroscience Research Australia Randwick, Sydney, NSW 2031, Australia. 52The University of Mississippi
Medical Center, Jackson, MS 39216, USA. 53Institute of Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald
17475, Germany. 54Department of Psychiatry, University of California, San Diego, La Jolla, CA 92093, USA. 55Departments of Physiology and
Nutritional Sciences, University of Toronto, Toronto, Ontario M5S 3E2, Canada. 56Department of Epidemiology, University of Washington, Seattle,
WA 98195, USA. 57Department of Health Services, University of Washington, Seattle, WA 98195-7660, USA. 58Kaiser Permanente Washington
Health Research Institute, Seattle, WA 98101, USA. 59Department of Biostatistics, University of Washington, Seattle, WA 98195, USA. 60Institute
for Translational Genomics and Population Sciences, Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA
90502, USA. 61Department of Pediatrics, Harbor-UCLA Medical Center, Torrance, 90509 CA, USA. 62Framingham Heart Study, Framingham, MA
01702, USA. 63Department of Neurology, Boston University School of Medicine, Boston, MA 02118, USA. 64University of Minnesota School of
Public Health, Minneapolis, MN 55454, USA. 65Kaiser Permanente Northern California Division of Research, Oakland, CA 94612, USA. 66Institute
of Cardiovascular and Medical Sciences, Faculty of Medicine, University of Glasgow, Glasgow G12 8QQ, UK. 67Department of Internal Medicine,
Erasmus MC University Medical Center, Rotterdam 3015, The Netherlands. 68Faculty of Medicine, CRC 1052 Obesity Mechanisms, University of
Leipzig, Leipzig 04103, Germany. 69German Center for Neurodegenerative Diseases (DZNE), Rostock/Greifswald 17475, Germany. 70Queensland
Brain Institute, University of Queensland, Brisbane, QLD 4072, Australia. 71Department of Psychiatry, Erasmus MC University Medical Center,
Rotterdam 3015 GD, The Netherlands. 72Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden 2300 RC, The Netherlands.
73Rotman Research Institute, Baycrest, Toronto, Ontario M6A 2E1, Canada. 74Departments of Psychology and Psychiatry, University of Toronto,
Toronto, Ontario M5T 1R8, Canada. 75Neuropsychiatric Institute, Prince of Wales Hospital, Randwick Sydney, NSW 2031, Australia. 76Department
of Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald 17475, Germany. 77Department of Neurology, University of
Washington, Seattle, WA 98195-6465, USA. 78Nuffield Department of Population Health, University of Oxford, Oxford, OX37LF, UK. 79Department
of Neurology, Erasmus MC University Medical Center, Rotterdam 3015 GD, The Netherlands
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-06234-w ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:3945 | DOI: 10.1038/s41467-018-06234-w |www.nature.com/naturecommunications 11
